Top Markets
#1 Wiki Cat Wiki Cat +26.34%
#2 Ribbita by Virtuals Ribbita by Virtuals +19.03%
#3 Bitway Bitway +18.16%
#4 PulseChain PulseChain +16.92%
#5 Velvet Velvet +16.49%
#6 TRIA TRIA +16.19%
#7 Cysic Cysic +16.06%
#8 Siren Siren +14.04%
#9 KUB Coin KUB Coin +13.60%
#10 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +13.59%
Coin of the day
Wiki Cat Wiki Cat
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc.

INTI
Clasificación en acciones #30838
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida,... Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
Precio por acción
$0.089
Última sincronización: 2026-08-17
Capitalización bursátil
$15.36M
Cambio (1 día)
50.59%
Cambio (1 año)
111.85%
País
US
Comercio Inhibitor Therapeutics, Inc. (INTI)

Categoría

Healthcare
Ingresos de Inhibitor Therapeutics, Inc. (INTI)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Inhibitor Therapeutics, Inc., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Inhibitor Therapeutics, Inc. desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE